Results 111 to 120 of about 6,532 (197)

12-month outcomes of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in rare CFTR missense variant. [PDF]

Genet Med Open
Vekaria S, Al-Abbasi H, Mulrennan S.
europepmc   +1 more source

Evaluating Long-Term Effectiveness of Cystic Fibrosis Modulator Therapies after Rapid Adoption: A Dual-Approach Study. [PDF]

Ann Am Thorac Soc
Miranda Afonso P, Zhou GC, Su W, Burgel PR, Cromwell E, Goss CH, Keogh RH, Liou TG, Marshall BC, Mayer-Hamblett N, Morgan WJ, Ostrenga JS, Pasta DJ, Schechter MS, Stanojevic S, Wainwright CE, Szczesniak RD, Andrinopoulou ER.   +17 more
europepmc   +1 more source

Effect of Elexacaftor/Tezacaftor/Ivacaftor Treatment on Extrapulmonary Complications of Cystic Fibrosis. [PDF]

Adv Ther
Geiger JM, Brady BL, Lew CR, Jennings M, Mo C, Van Brunt K, Dezube R.   +6 more
europepmc   +1 more source

Beyond BMI: Nutritional Recovery and Functional Implications of CFTR Modulators in Cystic Fibrosis. [PDF]

Biology (Basel)
Linguiti G, Granberg V, Leonetti G, Lassandro G, Lassandro M, Delvecchio M, Giordano P.   +6 more
europepmc   +1 more source

Post-marketing safety profile of lumacaftor/ivacaftor in cystic fibrosis treatment: a pharmacovigilance analysis based on FAERS. [PDF]

Front Med (Lausanne)
Wang T, Yang W, Luo Y, Zhan Y, Zou F, Cui Z, Lan Y.   +6 more
europepmc   +1 more source

Impact of COVID-19 and CFTR Modulators on Cystic Fibrosis: A Real-World Analysis of Care Patterns. [PDF]

Pediatr Pulmonol
Hinton AC, Sears EH, Lopez-Pintado S, Zuckerman JB.   +3 more
europepmc   +1 more source

Correction to: Improved quality of life in cystic fibrosis patients observed up to 36 months after starting Elexacaftor/Tezacaftor/Ivacaftor treatment. [PDF]

J Patient Rep Outcomes
Buniotto F, Tridello G, De Scolari A, Meneghelli I, Pintani E, Perobelli S, Cipolli M.   +6 more
europepmc   +1 more source

Prenatal Elexacaftor/Tezacaftor/Ivacaftor for Fetal Meconium Ileus: First Italian Case and Narrative Overview of the Emerging Evidence. [PDF]

J Clin Med
Boni A, Vassallo C, Ciciriello F, Cristiani L, Mancini A, Zucaro L, Graziano S, Goffredo BM, Alghisi F, Raponi M, Fabietti I, On Behalf Of Opbg Cf Pregnancy And Fetal Therapy Multidisciplinary Group.   +11 more
europepmc   +1 more source

Long-term impact of elexacaftor/tezacaftor/ivacaftor on small and large airways in people with cystic fibrosis aged ≥6 years: 24-month real-world evidence from the German Cystic Fibrosis Registry. [PDF]

ERJ Open Res
Dillenhöfer S, Schütz K, Burkhart M, Ellemunter H, Kappler M, Sieber S, Naehrlich L, Brinkmann F, Sutharsan S.   +8 more
europepmc   +1 more source

Impact of elexacaftor/tezacaftor/ivacaftor on gastrointestinal outcomes, inflammation, exocrine pancreatic function and fat malabsorption: Report of PROMISE pediatric substudy. [PDF]

J Cyst Fibros
Green N, Vu P, Xie J, Schwarzenberg SJ, Freedman S, Narkewicz M, Pittman J, Ratjen F, Rosenfeld M, Pope C, Duong J, Hoffman L, Heltshe S, Lusman SS, PROMISE Study Group.   +14 more
europepmc   +1 more source